Top Medical Research, Inc
Welcome,         Profile    Billing    Logout  
 1 Trial 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ruiz, Jose de Jesus Martinez
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Recruiting
3
440
Europe, Japan, US, RoW
Belimumab, BENLYSTA, GSK1550188, Placebo
GlaxoSmithKline
Lung Diseases, Interstitial
10/28
12/28
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
TRIUMPH-3, NCT05882045: A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease

Active, not recruiting
3
1800
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Cardiovascular Diseases
01/26
02/26
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Active, not recruiting
3
405
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteo Arthritis Knee
02/26
03/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
REZILIENT1, NCT04036682: A Phase 1/2 Trial of CLN-081 in Patients with Non-Small Cell Lung Cancer

Checkmark Data from a trial for NSCLC
Jan 2022 - Jan 2022: Data from a trial for NSCLC
Active, not recruiting
1/2
284
Europe, Japan, US, RoW
CLN-081, TAS6417; zipalertinib
Cullinan Therapeutics Inc.
Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
12/24
12/24
CLN-619-001, NCT05117476: A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Recruiting
1
410
Europe, US, RoW
CLN-619, Pembrolizumab
Cullinan Therapeutics Inc.
Advanced Solid Tumor
03/26
06/26
INORMUS_INTERNATIONAL, NCT02150980: INternational ORthopaedic MUlticenter Study in Fracture Care (INORMUS)

Completed
N/A
39797
RoW
McMaster University, Canadian Institutes of Health Research (CIHR), McMaster Surgical Associates, National Health and Medical Research Council, Australia, Hamilton Health Sciences Corporation
Fractures or Dislocations
11/23
11/23
ORACLE, NCT05059444: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Recruiting
N/A
1050
Europe, US
Guardant Reveal
Guardant Health, Inc.
Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Epithelial Ovarian Carcinoma, Fallopian Tube Carcinoma, Endometrial Carcinoma, Renal Cell Carcinoma, Rectal Adenocarcinoma
02/28
02/28

Download Options